Increased levels of glutamate causing excitotoxic damage accompany many neurological disorders. A well-characterized model of excitotoxic damage involves administration of kainic acid, which causes limbic seizure activity and subsequent neuronal death, particularly in the CA1 and CA3 areas of the hippocampus. Inhibition of the enzyme glycogen synthase kinase 3 (GSK-3) and cyclic AMP (cAMP) levels might play an important role in neuroprotection. Since intracellular cAMP levels depend, in part, on the activity of the phosphodiesterase enzymes (PDEs), these enzymes have recently emerged as potential therapeutic targets for the treatment of several diseases. In previous works we have shown a potent anti-inflammatory and neuroprotective effect of GSK-3 inhibition in a model of excitotoxicity, as well as a reduction of nigrostriatal dopaminergic neuronal cell death after phosphodiesterase 7 (PDE7) inhibition, which leads to an increase in cAMP levels. The present study was undertaken to determine whether simultaneous inhibition of GSK-3 and PDE7 by a novel 5-imino-1,2,4-thiadiazole compound, named VP1.14, could prevent the massive neuronal loss in the hippocampus evoked by intra-hippocampal injection of kainic acid.
The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an 
Introduction
Excitotoxicity is a well-characterized mechanism of neuronal death which has been implicated in different brain disorders, including neurodegenerative diseases (Coyle & Puttfarcken 1993 , Diehl et al. 1994 , Doble 1999 , Meldrum 2000 , Nakamura & Lipton 2010 ). An inflammatory response is often associated with kainic acid (KA)-induced hippocampal neurodegeneration. Activated glial cells increase the expression of genes implicated in the production of nitric oxide and proinflammatory cytokines, which in turn contribute to the expansion of brain injury and the increased loss of neurons (Oprica et al. 2003) .
Administration of KA into the hippocampus is a well-established model of excitotoxicity. KA injection is known to induce a sequence of behavioral changes, which are followed by neurodegeneration in specific brain regions, such as the hippocampus, piriform cortex, thalamus, and amygdala. A well-characterized pattern of neurodegeneration takes place in the hippocampus where the CA1 and CA3 pyramidal neurons and the interneurons of the hilus of dentate gyrus are the most vulnerable (Coyle 1983 , Sperk 1994 , Lau & Tymianski 2010 . Injection of KA into rodents also results in the activation of glial cells and inflammatory responses typically found in neurodegenerative diseases. Thus, this model has been widely used to analyze the cellular and molecular mechanisms that underlie central nervous system injury.
Accepted Article

© 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry
The suppression of neuroinflammation and induction of neuroprotection by GSK-3 inhibitors have been previously described (Luna-Medina et al. 2007a , Zhou et al. 2011 .
Moreover, GSK-3 inhibitors have been shown to possess preclinical efficacy in different animal models of neurodegenerative disorders, decreasing the microglial activation and reducing neuronal death (Martinez 2008) . In fact, tideglusib, a thiadiazolidinidione GSK-3 inhibitor, is on clinical trial phase IIb for Alzheimer's disease (Martinez 2008 , del Ser 2010 .
Different studies have suggested that cyclic AMP (cAMP) can actively play an important role in neuroprotection and in the modulation of the neuroinflammatory response observed after a brain injury (Lonze & Ginty 2002 , Volakakis et al. 2010 .
Thus, control of the levels of this nucleotide could generate the regulation of the pathological neuroinflammatory processes and, in consequence, the neuronal cell death that takes place in neurodegenerative disorders. Moreover, cAMP may activate the protein kinase A (PKA) signaling pathway leading to the inactivation of GSK-3 by its phosphorylation at Ser9 which, as commented above, also results in neuroprotection (Park et al. 2010 , Hayashi & Sudo 2009 ).
The cellular levels of cAMP depend on their synthesis by adenyl cyclases and their hydrolysis by cyclic nucleotide 3', 5'-phosphodiesterases (PDEs) (Conti & Beavo 2007 , Mehats et al. 2002 . Among the eleven families of PDEs, specifically PDE7 hydrolyzes cAMP and is highly expressed in the brain, being relatively abundant in the olfactory bulb, hippocampus, striatum and cerebellum (Miro et al. 2001 , Reyes-Irisarri et al. 2005 , Sasaki et al. 2002 . There is very little information regarding the physiological functions of PDE7. It has been suggested that this enzyme is involved in proinflammatory processes and that is necessary for the induction of T-cell proliferation. -Garcia et al. 2011) . Also, we have also shown that these quinazolines ameliorated brain damage and improved behavioral outcome in a cerebral artery occlusion stroke model (Redondo et al. 2012) .
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Given the limited understanding of PDE7 involvement in brain injury, the synergy recently shown between the increase of cAMP and the inhibition of GSK-3 (Lipina et al. 2012 ) and our previous speculation that both enzymes could play a crucial role in this process, in this work we sought to address the effects of VP1.14, a 5-imino-1,2,4-thiadiazole which inhibits both PDE7 and GSK-3 (Palomo et al. 2012) , after an excitotoxic injury in vivo and in vitro. Our findings demonstrate that in vivo administration of VP1.14 results in a reduced inflammatory response after kainic acid injection, and in a dramatic reduction in pyramidal cell loss in the CA1 and CA3
subfields of the hippocampus. In addition, our in vitro studies show that VP1.14 inhibits inflammatory activation of primary cultures of astrocytes and rescues HT22
hippocampal cells from an excitotoxic insult. obtained from our breeding facilities (normative ES280790000188) were used throughout the study.
Cell culture and treatments
Rat primary astrocyte cultures were prepared from the cerebral cortex of 2-day old rats as described previously (Luna-Medina et al. 2005 ) with minor modifications. Briefly, after removal of the meninges the cerebral cortex was dissected, dissociated, and incubated with 0.25% trypsin/EDTA at 37ºC for 1 h. After centrifugation, the pellet was washed three times with HBSS (Gibco) and the cells were plated on poly-D-lysine (20 μg/ml) pre-treated flasks (75 cm 2 ). After 7-10 days the flasks were agitated in an orbital shaker for 4 h at 230 rpm at 37°C and non-adherent microglial cells were removed.
Then DMEM was added to the flasks, which were agitated at 260 rpm at 37°C
overnight. The supernatant (oligodendrocytes and some remaining microglial cells) was The mouse hippocampal HT22 neuronal cell line (Invitrogen) was cultured in DMEM supplemented with 10% FBS and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) and incubated at 37ºC under 5% CO 2 . To perform the experiments of cell viability HT22 cells were seeded onto 96-well microplates (5 000 cells/well) overnight.
BRL-50481 (30 μM) or VP1.14 (3 µM) were added to the culture medium 2 h before exposure to glutamate (3 mM) and cells were incubated for 24 h before performing MTT assay.
Intrahippocampal injections
Adult male Wistar rats (2-3 month old) were used in this study. Rats (n ≥ 5 per group)
were anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and medetomidine (0.4 mg/kg) and placed into a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). KA (1 µg KA in 2.5 µl PBS, Sigma) alone or in
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posterior, -3.0 mm; lateral, -2.0 mm; depth, 3.5 mm; according to the atlas of Paxinos and Watson (Paxinos 1998) . The amount of S14 injected was calculated taking into account the distribution volume of 1ml and a concentration of 4μM, which is effective in the in vitro experiments (Supplementary Figure 1) . This concentration of VP1.14 did not significantly alter cell viability (Supplementary Figure 2) . Control animals of the same age were injected with vehicle. Rats were then housed individually to recover.
Immunohistochemistry
Seventy two hours after stereotaxic injection, the animals were anesthetized and 
Immunocytochemistry
At the end of the treatment period, primary astrocyte cultures, grown on glass coverslips, were washed with PBS, fixed for 30 min with 4% paraformaldehyde at 25°C and permeabilized with 0.1% Triton X-100 for 30 min at 37°C. After 1 h incubation with the corresponding primary antibody cells were washed with PBS and incubated with an Alexa-labeled secondary antibody (Invitrogen; 1:400) for 45 min at 37°C. Images were acquired using a LSM710 confocal microscope (Zeiss), with a 350 nm diode laser to excite DAPI (4, 6-diamidino-2-phenylindole) and a 488 laser to excite Alexa 488.
Confocal microscope settings were adjusted to produce the optimum signal to noise normalized to total nuclei. Areas to be counted were traced at high power (400X), and at least five different counting fields were selected at random per culture.
Nitrite measurements
To measure the levels of nitrite (NO 2 -) in astrocyte cultures after treatments, supernatants were collected and mixed with an equal volume of Griess reagent (SigmaAldrich).Samples were incubated for 15 min at room temperature and the absorbance was measured at 540 nm on a microplate reader.
Cell viability assay
For assessment of cell viability, a modified colorimetric MTT assay (Mosmann 1983) was used. This method is based on the ability of viable cells to reduce MTT (yellow solution) to formazan (dark blue crystals). After 24 h of treatment, HT22 cells were incubated with MTT solution (0.5 mg/ml PBS; Sigma-Aldrich) for 1 h at 37ºC, then aspirated and dimethyl sulfoxide was added and mixed thoroughly to dissolve dark blue crystals. The absorbance was read at 595 nm (wave long reference at 650 nm) with a microplate reader (Thermolab). The cell viability was expressed as a percentage relative to the control cells (cells not treated with glutamate).
Western blot
Proteins were isolated from cell cultures by standard methods. After electrophoresis, proteins were transferred to nitrocellulose membranes (Protran, Whatman) and blots were probed with the indicated primary antibodies, as previously described (Cortes- 
Statistical Determinations
Statistical comparisons for significance among different groups of animals were performed by ANOVA followed by Newman-Keuls'test for multiple comparisons. 
Results
Neuroprotective role of VP1.14 after excitotoxic brain injury
We studied the effect of VP1.14 in an established excitotoxic model in vivo. Adult rats received intrahippocampal injections of vehicle (PBS), KA or KA plus VP1.14 and animals were killed 72 h after injection. We first evaluated the extent of cell loss in the CA1 and CA3 regions of the hippocampus by Nissl staining (Fig 2A) . We observed an almost total preservation of CA1 neurons in VP1.14-injected rats, compared with more than 80% loss in KA-injected animals (Fig. 2B) . Regarding the CA3 region approximately 30% of the neurons survived in the VP1.14-injected animals. We further analyzed the extend of pyramidal neuronal cell death after excitotoxicity by staining with anti-NeuN antibody to detect surviving neurons, or with Fluoro-Jade B (Schmued et al. 1997 ) to detect degenerating neurons (Fig 3) . The VP1.14-injected rats exhibited
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© 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry significantly less damage in the CA1 and CA3 regions compared with the KA-injected rats, indeed there was no neuronal loss in CA1 and only a 30% loss in NeuN + cells in CA3 in contrast with a loss of 20 and 43% respectively in CA1 and CA3 of KA treated rats (Fig. 3A, C) . In agreement with these results, VP1.14-treated animals presented a diminished Fluoro-Jade B fluorescence in these regions of the hippocampus 72 h after KA injection (Fig 3B, D) , compared with the strong damage observed in KA-injected rats.
VP1.14 treatment inhibits glial activation
One of the events that take place in the hippocampus following excitotoxic injury is the sequential activation of microglia and astroglia. Microglial and astrocyte cells are considered to be key players in the induction of the neuronal damage following excitotoxic injury. Analysis of hippocampal sections revealed the expected accumulation of GFAP-positive astrocytes, 72 hours after KA injection, relative to vehicle-injected animals ( Figure 4A ). This increase in GFAP immunoreactivity was mainly detected in the CA1 and CA3 regions of the hippocampus. By contrast, VP1.14-treated rats displayed much less staining for GFAP, indicating a reduced astroglial response to KA-induced injury. Quantification of the data revealed a 2.4-fold decrease in the number of strongly-stained GFAP + astrocytes in the CA1 and CA3 regions. We also detected a similar decrease on GFAP staining intensity (Fig. 4C, D) .
In addition, the evaluation of CD11b staining for microglial infiltration revealed a considerably larger response in KA-injected rats than that found in those animals treated with VP1.14 ( Fig. 4B ). Quantitative studies (Fig. 4E) showed a 4-fold decrease in the number of CD11b-positive cells in the CA1 and CA3 of VP1.14-treated rats, compared with KA-injected rats
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VP1.14 protects hippocampal neurons from cell death and inhibits inflammatory activation of astrocyte cultures
We next examined the effect of VP1.14 in vitro on cell death in the murine hippocampal cell line HT22. As shown in Figure 5A , glutamate treatment resulted in a loss of cell viability, as assessed by a decline in MTT, as compared with control untreated cells.
Incubation with VP1.14 or BRL-50481, a well-known inhibitor of PDE7, caused a neuroprotective effect against glutamate-induced injury, as shown by an elevation in the cell viability of 20% and 27%, respectively (Fig 5A) .
The potential anti-inflammatory activity of VP1.14 was tested by studying nitrite production and the expression levels of two pro-inflammatory agents, IL-6 and COX-2, in primary cultures of astrocytes treated with glutamate or lipopolysaccharide (LPS). To measure nitrite production, astrocytes were incubated with VP1.14 or BRL-50481 for 2 h, and then cells were cultured for another 24 h with LPS. As shown in Fig. 5B , LPS treatment resulted in a 3.2-fold increase in the concentration of nitrites in the culture medium, which was significantly prevented by treatment with VP1.14 and BRL-50481.
To further evaluate the role of PDE7 inhibition in the inflammatory response in neural tissues, we tested the effects of VP1.14 and BRL-50481 on the expression levels of IL-6
and COX-2 in astrocyte cultures treated with glutamate (Fig. 6A,B) or LPS (Fig. 6 C,D). To this end, we performed immunofluorescence analysis followed by confocal microscopy. In basal conditions, IL-6 and COX-2 levels were barely detectable in astrocyte cultures, and their content was significantly induced after glutamate or LPS treatment. However, the number of astrocytes expressing IL-6 was significantly reduced
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© 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry (7.8-and 2.3-fold) in cultures treated with glutamate plus VP1.14 or BRL-50481, respectively. Similar results were observed in those cultures treated with LPS plus VP1.14 or BRL-50481. In parallel, we also observed a significant reduction in the number of cells expressing the pro-inflammatory enzyme COX-2 in those cultures treated with VP1.14 or BRL-50481, compared to glutamate-treated cultures. The effects of VP1.14 and BRL-50481 were not caused by a loss of cell viability, because the 24 h exposure of astrocyte cells to these compounds did not modify cell viability (Supplementary Figure 2) .
VP1.14 phosphorylates glycogen synthase kinase-3 (GSK-3)
It has been previously shown a synergistic interaction between PDE4, another cAMP hydrolyzing enzyme, and GSK-3 (Lipina et al. 2012) . We then analyzed whether VP1.14 could phosphorylate, and in consequence inactivate, GSK-3. As shown in 
Discussion
Here, we have shown that a novel thiadiazole derivative, VP1.14, which is a dual inhibitor of PDE7 and GSK-3, prevented both the glial activation and the neuronal cell death that occur in the hippocampus as a consequence of an excitotoxic insult. These results are further supported by in vitro studies directly demonstrating the antiinflammatory and neuroprotective effects of this compound. These results establish PDE7 as a factor involved in the development of excitotoxic injury and suggest a role for PDE7 as a novel target for treatment of brain disorders such as epilepsy, ischemia, and neurodegenerative diseases, in which excitotoxicity is involved (Coyle & Puttfarcken 1993 , Guo et al. 1999 , Lynch & Dawson 1994 , Hossmann 1994 . Glutamate is the driver of the excitotoxic process (Uryu et al. 2002) . Although 1995) . (Dawson & Dawson 1996) . Intrahippocampal injection of the excitotoxin kainic acid in rats is a common and well-characterized model of excitotoxicity. This treatment induces selective degeneration of hippocampal CA1 and CA3 pyramidal neurons and a significant fraction of dentate hilar neurons (Nadler et al. 1980 , Shetty & Turner 1996 . Our results show that dual GSK-3 and PDE7 inhibition clearly protects hippocampal neurons from KA-induced injury. In addition, VP1.14 protected the HT22 hippocampal neuronal cell line from glutamate injury.
One of the events associated to the neurodegeneration that takes place in several brain disorders is an inflammatory response, which is characterized by a reactive gliosis.
Activation of glial cells leads to the production of toxic substances, including the enzyme COX-2 and cytokines such as IL1β, IL-6, and TNF-α, that further damage neurons, leading to a cycle of inflammatory damage that ultimately worsens the progression of the disease (Dawson & Dawson 1996 ). This view is further supported by epidemiologic data showing that long-term treatment with non-steroidal antiinflammatory drugs may protect against Alzheimer disease and Parkinson disease (Townsend & Pratico 2005 , Chen et al. 2003 , Hald & Lotharius 2005 . Unfortunately, current therapies directed to treatment of brain injury do not address this neuroinflammation process.
The results presented here, demonstrate that VP1.14 treatment significantly reduces the accumulation of reactive astrocites and microglia in the hippocampus and the production of COX-2 and IL-6 induced by glutamate and LPS treatment in primary astrocytes. In this regard, our group has shown that the thiadiazolidinone (TDZD) compounds, which are GSK-3 inhibitors and also activators of the nuclear receptor Our results showing a phosphorylation of GSK-3 in serine9 by VP1.14 suggest that the observed effects of this compound could also be mediated by an inhibition of GSK-3. In this regard it has been previously shown that an inhibitor of PDE4B and a GSK-3 blocker synergize to produce antipsychotic effects on the Disrupted-In-Squizophrenia-1-L100P genetic model (Lipina et al. 2012 ). In addition, our group has recently demonstrated that the novel family of 5-imino-1,2,4-thiadiazoles is able to inhibit GSK-3 in a substrate competitive manner (Palomo et al. 2012) . Thus, our results indicate that VP1.14 could be acting through an inhibition of PDE7, which elevates cAMP levels, together with an inactivation of GSK-3 by a direct inhibition of this enzyme as well as by an inactivation through phosphorylation on Ser9 by the PKA enzyme. The fact that VP1.14 is targeting both PDE7 and GSK-3 enzymes may underlies the strong neuroprotective and anti-inflammatory activities of this compound.
In summary, our results demonstrate that a novel 5-imino-1,2,4-thiadiazole compound, through inhibition of PDE7 and GSK-3 enzymes, has a significant neuroprotective and anti-inflammatory effect in KA-injected rats, a well-characterized model of 
